These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25601433)

  • 1. Genetic modifiers of secondary iron overload in beta thalassemia major.
    Athiyarath R; George B; Abraham A; Viswabandya A; Srivastava A; Edison ES
    Blood Cells Mol Dis; 2015 Mar; 54(3):242-3. PubMed ID: 25601433
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy.
    Zarghamian P; Azarkeivan A; Arabkhazaeli A; Mardani A; Shahabi M
    BMC Med Genet; 2020 Apr; 21(1):75. PubMed ID: 32268883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of hepcidin gene expression in blood mononuclear cells with iron overload severity among β-thalassemia major patients.
    Ayatollahi H; Mousavi Nezhad SF; Talebpour A; Badiei Z; Nezami H
    Mol Biol Rep; 2020 Dec; 47(12):9353-9359. PubMed ID: 33231816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β-thalassemia.
    Athiyarath R; George B; Mathews V; Srivastava A; Edison ES
    Ann Hematol; 2014 Dec; 93(12):2093-5. PubMed ID: 24867648
    [No Abstract]   [Full Text] [Related]  

  • 5. Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia?
    Pelucchi S; Pelloni I; Arosio C; Mariani R; Piperno A
    Blood Cells Mol Dis; 2016 Mar; 57():112-4. PubMed ID: 26777753
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalassemia major: the iron irony.
    Stenner RC
    Haematologica; 2005 Oct; 90(10):1297A. PubMed ID: 16219550
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation of hepcidin level with insulin resistance and endocrine glands function in major thalassemia.
    Al-Hakeim HK; Al-Khakani MM; Al-Kindi MA
    Adv Clin Exp Med; 2015; 24(1):69-78. PubMed ID: 25923089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
    Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R
    Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of iron overload and genotype on gonadal function in women with thalassaemia major.
    Skordis N; Gourni M; Kanaris C; Toumba M; Kleanthous M; Karatzia N; Pavlides N; Angastiniotis M
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():292-5. PubMed ID: 16462714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation with oral deferiprone in patients with thalassemia.
    Grady RW; Giardina PJ
    N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum Hepcidin Levels in Children with Beta Thalassemia Major.
    Jagadishkumar K; Yerraguntla N; Vaddambal MG
    Indian Pediatr; 2018 Oct; 55(10):911-912. PubMed ID: 29941702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
    Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
    Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron-chelating therapy for transfusional iron overload.
    Musallam KM; Taher AT
    N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
    Liang Y; Bajoria R; Jiang Y; Su H; Pan H; Xia N; Chatterjee R; Lai Y
    Trop Med Int Health; 2017 Jun; 22(6):716-724. PubMed ID: 28544032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and Glucose Metabolism in Thalassemia Major: An Update.
    De Sanctis V; Soliman AT; Elsedfy H; Pepe A; Kattamis C; El Kholy M; Yassin M
    Expert Rev Hematol; 2016; 9(4):401-8. PubMed ID: 26697756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy.
    Chirico V; Lacquaniti A; Salpietro V; Luca N; Ferraù V; Piraino B; Rigoli L; Salpietro C; Arrigo T
    Eur J Endocrinol; 2013 Dec; 169(6):785-93. PubMed ID: 24014554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.